Suppr超能文献

多房性胸腔积脓的胸膜内纤维蛋白溶解治疗

Intrapleural fibrinolytic treatment of multiloculated thoracic empyemas.

作者信息

Robinson L A, Moulton A L, Fleming W H, Alonso A, Galbraith T A

机构信息

Section of Thoracic and Cardiovascular Surgery, University of Nebraska Medical Center, Omaha 68198-2315.

出版信息

Ann Thorac Surg. 1994 Apr;57(4):803-13; discussion 813-4. doi: 10.1016/0003-4975(94)90180-5.

Abstract

Acute multiloculated thoracic empyemas incompletely drained by tube thoracostomy alone usually require operation. To avoid a thoracotomy yet treat this difficult problem, intrapleural fibrinolytic agents were employed. Between April 1, 1990, and April 1, 1993, 13 consecutive patients presenting with a fibrinopurulent empyema were demonstrated to have incomplete drainage. To facilitate drainage, streptokinase, 250,000 units in 100 mL 0.9% saline solution (3 patients), or urokinase, 100,000 units in 100 mL 0.9% saline solution (10 patients), was instilled daily into the chest tube, and the tube was clamped for 6 to 12 hours followed by suction. This routine was continued daily for a mean of 6.8 +/- 3.7 days (range, 1 to 14 days) until resolution of the pleural fluid collection was demonstrated by computed chest tomography and clinical indications. This regimen was completely successful in 10 of 13 patients (77%), who had resolution of the empyema, eventual withdrawal of chest tubes, and no recurrence. Two patients, both pediatric liver transplant patients, had an initial good response but eventually required decortication. One patient with a good radiographic response became increasingly febrile during streptokinase therapy and underwent a thoracotomy, but no significant undrained fluid was found. This patient's continued fever was believed to be a streptokinase reaction. Urokinase was used subsequently. No treatment-related mortalities or complications occurred. Intrapleural fibrinolytic agents, especially urokinase, are safe, cost-effective means of facilitating complete chest tube drainage, thereby avoiding the morbidity of a major thoracotomy for 77% of a group of multiloculated empyema patients who traditionally would have required open surgical therapy.

摘要

单纯经胸腔闭式引流不能完全排出的急性多房性胸腔积脓通常需要手术治疗。为了避免开胸手术同时解决这一难题,采用了胸膜腔内纤溶药物。在1990年4月1日至1993年4月1日期间,连续13例出现纤维脓性脓胸的患者经证实存在引流不完全的情况。为促进引流,将25万单位链激酶溶于100 mL 0.9%盐溶液中(3例患者),或将10万单位尿激酶溶于100 mL 0.9%盐溶液中(10例患者),每日经胸管注入胸腔,胸管夹闭6至12小时后接负压吸引。该常规操作每日持续进行,平均6.8±3.7天(范围1至14天),直至胸部计算机断层扫描及临床指征显示胸腔积液消失。该方案在13例患者中的10例(77%)完全成功,脓胸消失,最终拔除胸管且无复发。2例患者均为小儿肝移植患者,最初反应良好,但最终需要行纤维板剥脱术。1例影像学反应良好的患者在链激酶治疗期间发热逐渐加重,接受了开胸手术,但未发现大量未引流的液体。该患者持续发热被认为是链激酶反应。随后使用了尿激酶。未发生与治疗相关的死亡或并发症。胸膜腔内纤溶药物,尤其是尿激酶,是促进胸腔闭式引流完全的安全、经济有效的方法,从而避免了传统上需要接受开放手术治疗的77%的多房性脓胸患者进行大手术的并发症。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验